Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford researchers have invented a novel concept to prevent or minimize scar formation during injury by controlling the mechanical environment through molecular targeting of mechanotransduction sensors including focal adhesion kinase (FAK).